» Articles » PMID: 33608002

Diabetic Phenotype and Prognosis of Patients with Heart Failure and Preserved Ejection Fraction in a Real Life Cohort

Overview
Publisher Biomed Central
Date 2021 Feb 20
PMID 33608002
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome, with several underlying etiologic and pathophysiologic factors. The presence of diabetes might identify an important phenotype, with implications for therapeutic strategies. While diabetes is associated with worse prognosis in HFpEF, the prognostic impact of glycemic control is yet unknown. Hence, we investigated phenotypic differences between diabetic and non-diabetic HFpEF patients (pts), and the prognostic impact of glycated hemoglobin (HbA1C).

Methods: We prospectively enrolled 183 pts with HFpEF (78 ± 9 years, 38% men), including 70 (38%) diabetics (type 2 diabetes only). They underwent 2D echocardiography (n = 183), cardiac magnetic resonance (CMR) (n = 150), and were followed for a combined outcome of all-cause mortality and first HF hospitalization. The prognostic impact of diabetes and glycemic control were determined with Cox proportional hazard models, and illustrated by adjusted Kaplan Meier curves.

Results: Diabetic HFpEF pts were younger (76 ± 9 vs 80 ± 8 years, p = 0.002), more obese (BMI 31 ± 6 vs 27 ± 6 kg/m, p = 0.001) and suffered more frequently from sleep apnea (18% vs 7%, p = 0.032). Atrial fibrillation, however, was more frequent in non-diabetic pts (69% vs 53%, p = 0.028). Although no echocardiographic difference could be detected, CMR analysis revealed a trend towards higher LV mass (66 ± 18 vs 71 ± 14 g/m, p = 0.07) and higher levels of fibrosis (53% vs 36% of patients had ECV by T1 mapping > 33%, p = 0.05) in diabetic patients. Over 25 ± 12 months, 111 HFpEF pts (63%) reached the combined outcome (24 deaths and 87 HF hospitalizations). Diabetes was a significant predictor of mortality and hospitalization for heart failure (HR: 1.72 [1.1-2.6], p = 0.011, adjusted for age, BMI, NYHA class and renal function). In diabetic patients, lower levels of glycated hemoglobin (HbA1C < 7%) were associated with worse prognosis (HR: 2.07 [1.1-4.0], p = 0.028 adjusted for age, BMI, hemoglobin and NT-proBNP levels).

Conclusion: Our study highlights phenotypic features characterizing diabetic patients with HFpEF. Notably, they are younger and more obese than their non-diabetic counterpart, but suffer less from atrial fibrillation. Although diabetes is a predictor of poor outcome in HFpEF, intensive glycemic control (HbA1C < 7%) in diabetic patients is associated with worse prognosis.

Citing Articles

Prevalence and prognostic significance of reduced myocardial perfusion reserve in diabetic heart failure with preserved ejection fraction using quantitative perfusion cardiac magnetic resonance.

Yang Y, Qin D, Li C, Tang L, Wang S, Chen X Eur Radiol. 2025; .

PMID: 40045071 DOI: 10.1007/s00330-025-11474-8.


Liraglutide combined with HIIT preserves contractile apparatus and blunts the progression of heart failure in diabetic cardiomyopathy rats.

Cai H, Dai C, Liu J, Chen S Sci Rep. 2025; 15(1):5051.

PMID: 39934246 PMC: 11814110. DOI: 10.1038/s41598-025-85699-4.


Myocardial Abnormalities Across the AHA/ACC Stages of Heart Failure in Patients With Diabetes.

Yang W, Zhu L, Wu W, Jiang M, Zhang H, Zhou D JACC Asia. 2025; 4(12):940-952.

PMID: 39803000 PMC: 11712003. DOI: 10.1016/j.jacasi.2024.08.016.


J-shaped association between serum glucose potassium ratio and prognosis in heart failure with preserved ejection fraction with stronger predictive value in non-diabetic patients.

Shan L, Zheng K, Dai W, Hao P, Wang Y Sci Rep. 2024; 14(1):29965.

PMID: 39622960 PMC: 11612494. DOI: 10.1038/s41598-024-81289-y.


Predictive Value of NT-proBNP, FGF21, Galectin-3 and Copeptin in Advanced Heart Failure in Patients with Preserved and Mildly Reduced Ejection Fraction and Type 2 Diabetes Mellitus.

Ianos R, Iancu M, Pop C, Lucaciu R, Hangan A, Rahaian R Medicina (Kaunas). 2024; 60(11).

PMID: 39597026 PMC: 11596953. DOI: 10.3390/medicina60111841.


References
1.
Pollock C, Lawrence J, Field M . Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus. Am J Physiol. 1991; 260(6 Pt 2):F946-52. DOI: 10.1152/ajprenal.1991.260.6.F946. View

2.
Hwang I, Cho G, Yoon Y, Park J, Park J, Lee S . Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. Cardiovasc Diabetol. 2020; 19(1):69. PMC: 7254690. DOI: 10.1186/s12933-020-01042-3. View

3.
Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

4.
Cencioni C, Spallotta F, Greco S, Martelli F, Zeiher A, Gaetano C . Epigenetic mechanisms of hyperglycemic memory. Int J Biochem Cell Biol. 2014; 51:155-8. DOI: 10.1016/j.biocel.2014.04.014. View

5.
Elder D, Singh J, Levin D, Donnelly L, Choy A, George J . Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study. Eur J Heart Fail. 2015; 18(1):94-102. DOI: 10.1002/ejhf.455. View